- Home
- XPO vs RPRX Comparison
XPO vs RPRX Comparison
Compare XPO & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPO | RPRX |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | XPO | RPRX |
|---|---|---|
| Price | $142.66 | $39.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 3 |
| Target Price | ★ $147.17 | $46.00 |
| AVG Volume (30 Days) | 1.3M | ★ 4.3M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.78 | 1.75 |
| Revenue | ★ $8,068,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $1.59 | $37.13 |
| Revenue Next Year | $3.74 | $1.48 |
| P/E Ratio | $51.41 | ★ $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $85.06 | $24.05 |
| 52 Week High | $161.00 | $41.24 |
Technical Indicators
Market Signals| Indicator | XPO | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 57.50 |
| Support Level | $130.02 | $39.24 |
| Resistance Level | $142.64 | $40.50 |
| Average True Range (ATR) | 5.60 | 0.91 |
| MACD | 0.66 | -0.08 |
| Stochastic Oscillator | 82.98 | 76.02 |
Price Performance
Historical ComparisonAbout XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.